Stock comparison
Genmab A/S
West Pharmaceutical Services
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
WST
West Pharmaceutical Services
Market cap
$22.35B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | WST | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 58C | GMAB |
| Benjamin Graham | 64C | 88A | WST |
| Philip Fisher | 48D | 47D | GMAB |
| Peter Lynch | 25F | 24F | GMAB |
| Joel Greenblatt | 76B | 60C | GMAB |
| Charlie Munger | 68C | 60C | GMAB |
| Terry Smith | 71C | 54C | GMAB |
Side-by-side metrics
| Metric | GMAB | WST |
|---|---|---|
| Market cap | $16.5B | $22.35B |
| P/E (TTM) | 6.2x | 39.8x |
| EV/EBIT | 12.0x | 34.0x |
| ROIC (TTM) | 43.78% | 15.24% |
| Gross margin | 93.88% | 36.24% |
| Net margin | 18.23% | 16.85% |
| Revenue CAGR 5y | -18.45% | 2.08% |
| EPS CAGR 5y | -23.48% | -6.4% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 0.0% | 0.29% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 39.8x+85%
- ROIC (TTM)43.78%vs 15.24%+65%
- EV/EBIT12.0xvs 34.0x+65%
- Gross margin93.88%vs 36.24%+61%
WST leads on
- Revenue CAGR 5y2.08%vs -18.45%+111%
- Dividend yield0.29%vs 0.0%+100%
- EPS CAGR 5y-6.4%vs -23.48%+73%
- Market cap$22.35Bvs $16.5B+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.